Phytochemical investigation on *Vitex negundo* leaves and their anti-inflammatory and analgesic activities

Tu Thanh Thi Nguyen^{®1,*}, Phuong Thi Do¹, Anh Van Thi Pham², Huong Giang Thi Tran Nguyen², Lan Ngoc Thi Nguyen³, Trang Tuyet Nguyen¹

¹Traditional Medicine Faculty, Hanoi Medical University, Hanoi, Vietnam, ²Department of Pharmacology, Hanoi Medical University, Hanoi, Vietnam, ³Department of Internal Medicine, Hanoi Medical University, Hanoi, Vietnam

The phytochemical investigation on *Vitex negundo* leaves has led to the isolation of one new iridoid glucoside (8 α -hydroxy-4-carboxyl-5 β H-9 β H-iridoid-1 α -*O*-(6'-*O*-(6,7-dihydrofoliamenthonyl)- β -D-glucopyranoside, **3**), together with three known compounds, namely agnuside (1), 6'-*O*-*E*-caffeoylmussaenosidic acid (2), and 3,5-dicaffeoylquinic acid (4). The HPLC analytical study was also performed to quantify the content of agnuside (1) in dried leaves. The results indicated the very high content of **1** (3.04 ± 0.02%). The method was also validated by various parameters, including linearity (R²= 0.9999), precision (intra-day RSD ≤ 2.50%, inter-day RSD= 0.76%), and accuracy (recovery rates 96.58-101.86%). The animal testing data showed that the extract did not reduce pain at the doses of 9.6 and 28.8 g /kg (leaf weight/body weight) in the hot plates and pain measuring models but showed the pain reduction in the acetic acid-induced pain model. The extract at the dose of 5.6 g/kg (leaf weight/body weight) also had effects on the acute inflammation in the carrageenin-induced edema model. The extract at the dose 9.6 and 28.8 g/kg (leaf weight/body weight) also had effects on the acute inflammation in the carrageenin-induced edema model. The extract at the dose 9.6 and 28.8 g/kg (leaf weight/body weight) also had effects on the acute inflammation in the carrageenin-induced edema model. The extract at the dose 9.6 and 28.8 g/kg (leaf weight/body weight) also had effects on the acute inflammation in the carrageenin-induced edema model. The extract at the dose 9.6 and 28.8 g/kg (leaf weight/body weight) also had effects on the acute inflammation in the carrageenin-induced edema model. The extract at the dose 9.6 and 28.8 g/kg (leaf weight/body weight) also showed significant chronic anti-inflammation, comparable to methylprednisolone at the dose 10 mg/kg on the mouse peritoneal.

Keywords: Vitex negundo. Iridoid. HPLC quantification. Anti-inflammatory. Analgesic.

INTRODUCTION

3JPS

Vitex negundo L. was a shrub or small tree which was available in the plains, mountainous area and in the midland of Vietnam. It has been widely used in treatment of many diseases such as arthritis, flu, fever, cough, asthma, sprains, and colitis (National Institute of Medicinal Materials, 2006; Vu, 2007). The published chemical studies on *V. negundo* showed the wide spectrum of its compounds, such as iridoid glycosides, quinic acid derivatives, flavonoids, and lignans (Hu *et al.*, 2016; Hu *et al.*, 2017; Zheng, C.J. *et al.*, 2015). There were also pharmacological studies on analgesic and anti-inflammatory properties of this plant (Chattopadhyay *et al.*, 2012; Dharmasiri *et al.*, 2003; Gill *et al.*, 2018). In Vietnam, so far, no study has been conducted on the compounds of this plant as well as its pharmacological activities. With the potential clinical application and consideration of available studies on this plant, the present study was conducted to give more insights into compounds of *V. negundo* collected in Vietnam, analytical method for quantification of main compounds, as well as its analgesic and anti-inflammatory properties in the different animal models, in order to provide firm scientific support for traditional usage, clinical application, and quality control procedure in Vietnam.

MATERIAL AND METHODS

General experimental procedures

NMR experiments were conducted on a Bruker Avance III HD (400 MHz) spectrometer (Bruker)

^{*}Correspondence: Email: thanhtu@hmu.edu.vn

operating at 400 MHz (¹H) and 100 MHz (¹³C), the samples were dissolved in methanol-*d*4. HRESIMS spectra were recorded on a micrOTOF-Q II (Bruker) operated by Hystar software. Optical rotation was measured on a Jasco P-2000 polarimeter with 10 cm path length. Chromatography was performed on open column, with normal-phase and reverse-phase columns (RP-C18), as well as with Sephadex LH-20 (Sigma-Aldrich). The HPLC analysis was performed on an Agilent HPLC system 1200 series (Agilent, USA). All of solvents used for extraction and isolation were redistilled for suitable quality. Solvents for analytical experiments were obtained from Merck.

Plant material

The *Vitex negundo* leaves were collected in the outskirts of Hanoi, Vietnam. The sample was taxonomically authenticated by Prof. Phuong Xuan Vu from the Institute of Ecology and Biological Resources, Hanoi, Vietnam. The voucher specimens (HMU-VN2018-01) was deposited in the Institute of Ecology and Biological Resources, Hanoi, Vietnam.

Extraction and isolation

The dried V. negundo leaves (500 g) were extracted by MeOH in ultrasonic bath (3 times \times 2 L \times 2h). The extracts were combined and evaporated under the low pressure to obtain 70.8 g of green slurry. The crude extract was suspended in distilled water and partitioned with EtOAc. The organic solvent layer was then evaporated to vield EtOAc-soluble portion (22.5 g). The EtOAc portion was fractionated by normal-phase silica gel column (5×40 cm, 40-63 µm), eluting with gradient solvent system of EtOAc/ MeOH (from 30:1 to 0:1) to obtain 10 subfractions (F1-10). Fraction F5 (1.2 g) was firstly subjected into RP-C18 column (1.5×60 cm, 40-63 µm) with gradient MeOH/ H2O (from 30-80%), then purified by Sephadex LH-20 column (1.5×60 cm, MeOH) to obtain compounds 2 (24.4 mg) and 4 (48.7 mg). Fraction 6 (2.5 g) was also purified using the same procedure to obtain compounds 1 (10.7 mg) and 3 (7.7 mg).

8α-hydroxy-4-carboxyl-5βH-9βH-iridoid-1α-O-(6'-O-(6,7-dihydrofoliamenthonyl)-β-D-glucopyranoside (3) Brownish gum; -8.8 (*c* 0.05, MeOH); UV λmax 236,
262 nm; CD (40 µM, MeOH, mdeg) 203 (+0.44), 229 (-6.02),
255 (+0.64); ¹H and ¹³C NMR see Table I; HR-ESIMS *m/z*543.2418 [M-H]⁻ (cacld. for C26H39O12 543.2447).

TABLE I - NMR data for 3 (400/100 MHz, MeOH-d4)

Position	3							
	δ _H	mult., J	δ _c	type				
1	5.49	d, 2.0	93.4	d				
3	7.22	d, 0.8	149.8	d				
4	-	-	112.6					
5	2.94	m	29.6	d				
6	1.27 1.47	m m	m 35.5					
7	1.57 1.60	m m	40.2	t				
8	-	-	78.3	S				
9	2.24	m	51.1	d				
10	1.25	S	22.8	q				
11	-	-	168.7	S				
1′	4.84	d, 7.6	96.3	d				
2′	4.77	dd, 8.0, 9.6	73.4	d				
3'	3.58	m	74.5	d				
4′	3.36	m	70.4	d				
5'	3.37	m	77.1	d				
6′	3.69 3.91	m m	61.3	t				
1″	-	-	167.2	S				
2″	-	-	126.9	S				
3″	6.77	dt, 1.6, 7.6	143.2	d				
4″	2.21	m	25.9	t				
5″	1.27 1.47	m m	35.5	t				
6″	1.61	m	29.1	d				
7"	1.36 1.59	m m	39.2	t				
8″	3.61	m	59.6	t				
9″	1.79	S	11.1	q				
10″	0.95	d, 6.4	18.4	q				

HPLC quantification method

Standard solution

Reference compound 1 was isolated in-house by various means of chromatography. The standard compound had a purity \geq 95% as determined by HPLC and NMR. The stock standard solution was freshly prepared in methanol with concentration approximately 1.0 mg/mL. These steps of standard solution were prepared from the stock by diluting with methanol.

Sample preparation

Powdered plant material (50 mg) was extracted sonically with methanol ($3.0 \text{ mL} \times 20 \text{ min} \times 3 \text{ times}$). After centrifugation (2800 rpm, 2 min), the supernatants were combined in a 10 mL volumetric flask. Before analysis, each sample solution was filtered through 0.4 µm membrane.

Analytical conditions

The optimal separation was determined as follows: on column Phenomenex Synergi 4u MAX-RP 80A (150×4.60 mm, 4 μ m) protected by a 0.2 μ m guard filter (Waters) at 40°C. The mobile phase was consisted of water containing 0.02% trifluoroformic acid (A) and acetonitrile (B). The gradient was from 12B/88A to 16B/84A in 35 min. The column was then washed with acetonitrile and re-equilibrated with initial solvent system for 15 min before the next analysis. The injected volume of sample was 10 μ L, the flow rate was set at 0.6 mL/ min. The UV detector was set at 258 nm

Method validation

The method validation was conducted for various criteria, including linearity, the limits of detection (LOD) and quantification (LOQ), accuracy, and precision. The calibration curve was established with a stock solution of compound **1** (approximately 1.0 mg/mL) prepared in methanol and five further levels obtained by serially diluting with methanol (1:1). Linearity was calculated based on six concentrations and their respective HPLC

peak area. The LODs and LOQs were visually determined as 3-times and 10-times signal-to-noise ratio, respectively. Peak purity was determined by 'Peak Purity' function in Agilent software with threshold set at 950. Intra- and interday precisions were evaluated on three consecutive days, each sample was examined in triplicate. The accuracy of method was evaluated by spiking three different volumes of **1** (1 mg/mL) into plant materials sample (high spike: 1000 μ L; medium spike: 500 μ L; low spike: 250 μ L).

Statistical analysis

All samples were analyzed in triplicate. The analyzed data was expressed in the form "mean \pm standard deviation (SD)". The data was calculated and processed by Microsoft Excel 2016 (Microsoft, USA).

Extract preparation for animal testing

Plant materials (5 kg) were crushed into small pieces and extracted by 70% aqueous ethanol under flux 3 times (solvent/ material ratio= 6/1). The combined extract was then evaporated under reduced pressure to two thirds of original volume and stirred for 24 hours. After that, the extract was filtered to remove settled resin and evaporated to remove completely organic solvent in order to obtain concentrated extract.

Experimental animals

Healthy mature Swiss mice (weights, 18-22 g), and mature Wistar rats (weights, 100-150 g), of both sexes were provided by the National Institute of Hygiene and Epidemiology (Hanoi, Vietnam). Animals were acclimated 5-7 days before experiments.

The experiments were carried out in the Department of Pharmacology, Hanoi Medical University, Vietnam. Animal research protocols were approved by the Ethical Council of Hanoi Medical University, Vietnam.

Hot plate test and gauge pain threshold

The mice were divided into 4 groups and administrated orally using gavage. Group I drank

distilled water as the control at the dose of 0.2 mL/10g; Group II drank codeine phosphate at a dose of 20 mg/ kg; Group III, IV drank extract of *V. negundo* leaves at the dose of 9.6, 28.8 g/kg (leaf weight/body weight), respectively.

The heat sensitivity of mice was evaluated by hot plate test to measure the response time to temperature of mice one hour before and after the last treatment. The animals are plated on the hot plate (always maintained at 56°C) and the time until either licking or jumping occurs was recorded by stopwatch. The mice that responded too quickly (before 8 seconds) or too slowly (after 30 seconds) were then eliminated. The reaction time with heat stimulation before and after the administration of the *V. negundo* extracts (in seconds) was then compared among mice groups (Ankier, 1974; Vogel, 2008).

The pressure pain threshold was measured using Dynamic Plantar Aesthesiometer in which an ascending force was applied to the right paw of the mice. The distance was recorded by observing on the scale the force at which the animal felt pain (Ankier, 1974).

Acetic acid-induced writhing

White mice were divided into 4 groups each containing ten rats: group I drank distilled water as the control at the dose of 0.2 mL/10g; group II drank aspirin 150 mg/kg; group III, IV drank extract of *V. negundo* leaves at the dose of 9.6, 28.8 g/kg (leaf weight/body weight), respectively. The mice in the groups I, III and IV were drinking distilled water or the reagents once a day in the morning for three consecutive days. On the third day, one hour after taking the substance, 0.2 mL of acetic acid 1% was injected to mice's abdominal cavities. The number of cramping pain episodes in each mouse was counted every 5 minutes for 30 minutes after the injection of acetic acid, then was compared to the control groups (Koster, Anderson, de Beer, 1952).

Anti-inflammatory activity

The acute anti-inflammatory activity of the V. negundo leaves were evaluated in the carrageenan-

induced rat paw edema model and the peritonitis rat model (Winter et al., 1962). Each model was divided into 4 groups: Group I drank distilled water as the control at the dose of 1 mL/100g; Group II drank aspirin 200 mg/kg; Group III, IV drank the V. negundo leaves at the doses of 5.6 and 16.8 g/kg/day (leaf weight/ body weight/day), respectively. Rats were given the V. negundo leaves or water or aspirin for 4 days before inducing inflammation. For the carrageenan-induced rat paw edema model, on the fourth day, one hour after taking the V. negundo leaves, 0.05 mL of 1% solution of carrageenan was injected into the right hind soles of the rat. The volume of rat paw was observed before inducing inflammation (V0), 2 hours after inducing inflammation (V2), 4 hours (V4), 6 hours (V6) and 24 hours (V24) by using a Plethysmometer.

The increase of rat paw volume was calculated by following formula

$$\Delta V\% = \frac{V_t - V_0}{V_0} \times 100$$

 V_0 : rat paw volume before inducing rat paw edema V_i : rat paw volume after inducing rat paw edema

The anti-inflammatory activity of the drugs was expressed as percentage inhibition (I%), which was calculated as follows:

$$I\% = \frac{\Delta \overline{V}_c \% - \Delta \overline{V}_t \%}{\Delta \overline{V}_c \%} \times 100$$

 $\Delta \overline{V}_c$ %: Average increase in rat paw volume in control group $\Delta \overline{V}_t$ %: Average increase in rat paw volume in treated group

In the peritonitis rat model, on the fourth day, one hour after taking the *V. negundo* leaves, 2 mL of solution of carrageenan (50 mg carrageenan and 1.4 ml formaldehyde mixed enough in 100ml saline solution) was injected into the peritonitis of the rat. One day after causing inflammation, inflammatory exudate was taken from the abdomen of the mouse. The number of leukocytes in 1 mL of inflammatory exudate was counted (Vogel, 2008).

The chronic anti-inflammatory effects were studied on experimental granulomas model (Vogel, 2008). In detail, chronic inflammation was induced by implanting sterile asbestos fibers weighed 6 mg which were soaked in 1% carrageenan into the skin of each mouse nape. The treatment groups included Group I drank distilled water 0.2 mL/10g; Group II drank methylprednisolone 10 mg/kg; Group III, IV drank the V. negundo leaves at the doses of 9.6, 28.8 g/kg/day (leaf weight/body weight/ day), respectively. The mice then drank distilled water or the reagents continuously for 10 days. On the eleventh day, mice were sacrificed in order to collect granuloma. Three granulomas in each group were randomly selected for microscopic pathological observation. The remaining granulomas were dried at 56°C for 18 hours then weigh after being dried. Results were expressed as percentage inhibition of granuloma in drug treated groups compared to the control group, which was calculated as follows:

inhibition of granuloma = $1 - \frac{GT}{GC} \times 100$

GT: granuloma tissue weight in treated group, GC: granuloma tissue weight in control group.

Statistical analysis

Data was shown as mean \pm standard error (mean \pm SE). The data was evaluated Independent Samples T-Test using SPSS program (version 18. SPSS Inc., USA). The differences were statistically significant with p < 0.05.

RESULTS AND DISCUSSION

Structural elucidation of new compound

Phytochemical investigation on *V. negundo* leaves have resulted in the isolation of 4 compounds (1-4) (Figure 1). The structures of isolated compounds were determined by NMR spectroscopic analysis and comparison with published data, specifically, agnuside (1), 6'-*O*-*E*-caffeoylmussaenosidic acid (2), 8 α -hydroxy-4-carboxyl-5 β H-9 β H-iridoid-1 α -*O*-(6'-*O*-(6,7-dihydrofoliamenthonyl)- β -D-glucopyranoside (3), and 3,5-dicaffeoylquinic acid (4). Compound **3** was identified as a new natural product.



FIGURE 1 - Structures of compounds isolated from V. negundo leaves.

Compound 3 was isolated as a brownish gum. Its chemical formula was determined as $C_{26}H_{40}O_{12}$ by a negative charged peak [M-H] at m/z 543.2418 (cacld. for $C_{26}H_{20}O_{12}$ 543.2447) in the HR-ESI mass spectrum. The ¹H NMR spectrum showed two olefinic protons [$\delta_{\rm H}$ 7.22 (1H, d, J= 0.8 Hz) and $\delta_{\rm H} 6.77 (1H, dt, J= 1.6, 7.6 Hz)],$ one characteristic proton [$\delta_{\rm H}$ 5.49 (1H, d, J= 2.0 Hz)], one anomeric sugar proton [δ_{H} 4.84 (1H, d, J= 7.6 Hz)], and three methyl groups [δ_{H} 1.79 (3H, s), 1.25 (3H, s), and 0.95 (3H, d, J= 6.4 Hz)]. The ¹³C NMR spectrum showed 26 signals, including two carbonyl (δ_c 168.7 and 167.2), four olefinic $(\delta_{c}$ 149.8, 143.2, 126.9, and 112.6), and 9 oxygenated $(\delta_{c}$ 96.3, 93.4, 78.3, 77.1, 74.5, 73.4, 70.4, 61.3, and 59.6). The COSY indicated three chain coupling systems, including H-1/H-9/H-5/H-6/H-7; H-1'/ H-2'/ H-3'/ H-4'/ H-5'/ H-6'; and H-3"/ H-4"/ H-5"/ H-6"(H-10")/ H-7"/ H-8" (Figure 2). The key HMBC correlations of H-1 ($\delta_{\rm H}$ 5.49) /C-3 $(\delta_{\rm C}$ 149.8), H-3 $(\delta_{\rm H}$ 7.22)/C-11 $(\delta_{\rm C}$ 168.7) and C-5 $(\delta_{\rm C}$ 29.6), and H-10 ($\delta_{\rm H}$ 1.25)/ C-7 ($\delta_{\rm C}$ 40.2), C-8 ($\delta_{\rm C}$ 78.3), and C-9 $(\delta_{c}$ 51.1) strongly suggested an iridoid skeleton (Figure 2). The sugar moiety was connected to the aglycon at C-1 position, which was determined by an HMBC correlation from H-1 (δ_{H} 5.49) to C-1' (δ_{C} 96.3). Additionally, the down fielded chemical shift of H-2' ($\delta_{\rm H}$ 4.77) and an HMBC correlation of H-2' ($\delta_{\rm H}$ 4.77)/ C-1" ($\delta_{\rm C}$ 167.2) indicated the esterification at C-2 position sugar. The substitution was identified as 6,7-dihydrofoliamenthonyl by a COSY chain coupling network H-3"/ H-4"/ H-5"/ H-6"(H-10")/ H-7"/ H-8" and series of HMBC correlations of H-9" ($\delta_{_{\rm H}}$ 1.79)/ C-1" ($\delta_{_{\rm C}}$ 167.2), C-2" ($\delta_{_{\rm C}}$ 126.9), and C-3" ($\delta_{_{\rm C}}$ 143.2) (Wang et al., 2017).

The relative configuration of **3** was established by NOESY and coupling constant analysis. The NOESY cross peaks of H-9/ H-5. H-10, and H-1 indicated that these four protons were in the same orientation (Figure 3). The small coupling constant of H-1 [$\delta_{\rm H}$ 5.49 (1H, d, *J*= 2.0 Hz)] indicated the *cis*-orientation of H-1 and H-9, which also supported the relative configuration (Yang *et al.*, 2006). The sugar was determined as β -D-glucopyranose by NOESY correlations of H-1"/ H-3" and H-5"; H-2"/ H-4", and by large coupling constant of anomeric proton (*J*= 7.6 Hz), as well as by comparison with published data (Xiong *et al.*, 2015). Collectively, the structure of **3** was established as 8α -hydroxy-4-carboxyl-5 β H-9 β Hiridoid-1 α -*O*-(6'-*O*-(6,7-dihydrofoliamenthonyl)- β -Dglucopyranoside, a new iridoid glucoside.



FIGURE 2 - Selected HMBC (H \rightarrow C) and ¹H-¹H COSY correlations of compound **3**.



FIGURE 3 - Key NOESY correlations of aglycon of 3.

HPLC quantification and method validation

The optimal separation was determined as follows: on column Phenomenex Synergi 4u MAX-RP 80A (150×4.60 mm, 4µm) protected by a 0.2 µm guard filter (Waters) at 40°C. The mobile phase was consisted of water containing 0.02% trifluoroformic acid (A) and acetonitrile (B). The gradient was from 12B/88A to 16B/84A in 35 min. The column was then washed with acetonitrile and re-equilibrated with initial solvent system for 15 min before the next analysis. The injected volume of sample was 10 μ L, the flow rate was set at 0.6 mL/ min (Figure 4). The UV detector was set at 258 nm. The content of **1** in experimental sample was determined 3.04 ± 0.02% (dried weight).

The proposed method was also validated by various parameters, including linearity ($R^2=0.9999$), limits of detection (LOD= 0.045 µg/mL), limits of quantification (LOQ= 0.135 µg/mL), precision (intra-day RSD $\leq 2.50\%$, inter-day RSD= 0.76%), and accuracy (recovery rates of high spike 96.58%, medium spike 101.86%, and low spike 98.94%) (Table II). All parameters were in good range for validation.



FIGURE 4 - HPLC chromatogram of standard compound **1** and methanol plant extract. HPLC conditions: Agilent HPLC system 1200 series system (USA); Column: Phenomenex Synergi 4u MAX-RP 80A (C12, 150×4.60 mm, 4µm); column temperature: 40°C; mobile phase 12B/88A to 16B/84A in 35 min [0.02% trifluoroformic acid in water (A) and acetonitrile (B)]; injection volume: 10 µL, flow rate: 0.6 mL/ min; UV wavelength: 258 nm; Sample: 50 mg leaves/ 10 mL MeOH.

Parameter / Compound	1					
Regression equation	y = 30167x - 81.807					
σ_{rel} of slope	1.38					
\mathbb{R}^2	0.9999					
Range (µg/mL)	1055-32.7					
LOD (µg/mL)	0.045					
LOQ (µg/mL)	0.135					
Accuracy ¹						
High spike	96.58					
Medium spike	101.86					
Low spike	98.94					
Precision						
Intra-day ²	2.50					
Inter-day	0.76					

TABLE II - Validation parameters of HPLC quantification of V. negundo leaves

¹ expressed as recovery rates in percent.

² maximum relative standard deviation (peak area) within one and three consecutive days (n = 3).

Abbreviations: y = peak area, x = concentration (mg/mL), $\sigma rel = relative standard deviation$, $R^2 = \text{determination}$ coefficient, LOD = limit of detection, LOQ = limit of quantification.

Analgesic activity

The results reported in the Figure 5 showed that the extract of *V. negundo* leaves in both 2 doses of 9.8 g/kg/day (leaf weight/body weight/day) and 28.8 g/kg/ day (leaf weight/body weight/day) taken orally for 3 consecutive days were significantly effective in reducing a number of writhing induced by 0.2 mL acetic acid 1% at all times of study, compared to control group (p < 0.05, p < 0.01, and p < 0.001), indicating the peripheral analgesic activity of the extract. However, the Figure 6 and Figure 7 showed that the extract of *V. negundo* leaves showed no central analgesic activity in hot plate method and pressure pain threshold on mice with the doses of 9.6 and 28.8 g/kg/day (leaf weight/body weight/day) orally for three consecutive days.



FIGURE 5 - Effects of the V. negundo leaves on acetic acid-induced writhing in mice

(Presented as Mean \pm SE (n=10). Statistical analysis: *: p < 0.05, **: p < 0.01, ***: p < 0.001, T- test as compared to control)



FIGURE 6 - Analgesic effect of the V. negundo leaves on mice by the hot plate method.

(Presented as Mean \pm SE (n=10). Statistical analysis: *: p < 0.05, T- test as compared to control)



FIGURE 7 - Analgesic effect of the *V. negundo* leaves on mice by pressure pain threshold. (Presented as Mean \pm SE (n=10). Statistical analysis: **: p < 0.01, T- test as compared to control)

Anti-inflammatory activity

Acute anti-inflammatory activity

Acute anti-inflammatory effects were measured on the white rat with carrageenan-induced edema paw model. The reduced percentages of edema paw volume were presented in the Figure 8. In the control group (group 1), carrageenan injection was used to induce a local edema, which progressively increased after 2, 4, and 6 hours to 42.1, 60.8, and 69.0%, respectively. Afterwards, the edema decreased, but still remained after 24 hours. The pretreatment by administering the *V. negundo* leaves orally with the dose of 5.6 g/kg (leaf weight/body weight) on rat significantly decreased the paw edema levels by 10.5, 18.3, and 41.2% after 2, 4, and 6 hours, respectively.



FIGURE 8 - Effects of the V. negundo leaves on edema volume in carrageenan-induced inflammation.

(Presented as Mean \pm SE (n=10). Statistical analysis: *: p < 0.05, **: p < 0.01, T- test as compared to control)

Influence of V. negundo leaves on the number of leukocytes in inflammatory exudate

The results in the Figure 9 showed that the extract of *V. negundo* leaves with the dose of 16.8 g/kg

(leaf weight/body weight) reduced significantly the number of leukocytes in inflammatory exudate. When compared to control group (p < 0.05), the reduction was 32.23%.





(Presented as Mean \pm SEM (n=10). Statistical analysis: *: p < 0.05, T- test as compared to control)

Chronic anti-inflammatory effects of the V. negundo leaves

The results in the Figure 10 showed that the extract of *V. negundo* leaves with the doses of 9.6 g/kg (leaf

weight/body weight), and 28.8 g/kg (leaf weight/body weight), reduced 40.20% and 41.24% granulomas weight when compared to control group, which indicated the activity against chronic inflammation (p < 0.01).



FIGURE 10 - Effects of the V. negundo leaves on granulomas weight.

(Presented as Mean \pm SE (n=10). Statistical analysis: **: p < 0.01, ***: p < 0.001, T- test as compared to control)

DISCUSSION

The purpose of this study was to establish a firm scientific basis for the usage of *V. negundo* for treatment of anti-inflammatory conditions in Vietnam. This was a necessary task because *V. negundo* has been widely used in Vietnamese community, however, little was known about its compounds, as well as pharmacological activity of this species cultivated in Vietnam. The phytochemical investigation on *V. negundo* leaves collected in Vietnam revealed that the major components are iridoid glucosides (1-3) and quinic acid (4) derivatives. Agnuside (1) was determined to be the major constituents in *V. negundo* leaves sample collected in Vietnam with very high content (approximately 3%). The HPLC quantification method was also validated according to ICH guideline

(International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005)2005. Besides that, a new natural iridoid (**3**) was also isolated and structurally elucidated by combination spectroscopic and spectrometric methods (1D, 2D-NMR, HRMS).

Iridoid was a group of natural compounds that was well known for analgesic and anti-inflammatory activities in *in vivo* models (Baghdikian *et al.*, 1997; Lanhers *et al.*, 1992; Wang *et al.*, 2014; Zheng, Y. *et al.*, 2015). The mechanism was believed via inhibition of cyclooxynase-2 (COX-2), inducible nitric oxide synthase (iNOS), and 5-lipoxygenase (5-LO) (Ryu *et al.*, 2010). Besides that, the major composition, agnuside (1), was an iridoid glucoside linking with a 4-hydroxybenzoic acid moiety, which was well-studied for the analgesic activity in acetic acid-induced writhing model in mice (56% inhibition, p< 0.001 at the dose of 50 mg/kg) (Okuyama *et al.*, 1998). Therefore, the quantification of agnuside content showed significant values in quality control of this plant and its related herbal products. An HPLC quantification method was also developed and validated, which gave the result of content of agnuside (1) in dried leaves of *V. negundo* ($3.04 \pm 0.02\%$). The validation parameters were in good range for quantification (See Table II).

The extract was further examined in animal models for analgesic and anti-inflammatory activities. The V. Negundo leaves showed no statistically significant difference in response time in hot plate method at the both doses of 9.6 and 28.8 g/kg (leaf weight/body weight), indicating that the extract did not possess analgesic effect on the central nervous system in the experimental models. On the contrary, the extract did reduce the number of cramping pain attacks in the writhing mouse tests. The pain inducing experiment with acetic acid was representative in evaluating the peripheral analgesic activity, proving that the extract displayed effect on the peripheral mechanism at the experimental doses (9.6 and 28.8 g/kg). These results were in good agreement with previous pharmacological study results. Agnuside isolated from V. rotundifolia fructus showed significant writhing inhibition with oral administration at dose of 50 mg/kg (Okuyama et al., 1998). Gupta and Tandon (2005) also reported that at the dose of 500 mg/kg (extract weight/ body weight), V. negundo leaves extract was shown to delay writhing onset and significantly reduce the number of acetic acid-induced writhings (Gupta, Tandon, 2005).

As for anti-inflammatory activities, *V. negundo* leaves extract showed potent effects in carrageenaninduced edema rat model. The volume of rat paw edema significantly decreased by 41.16% with the dose of 5.6 g/kg (leaf weight/body weight), compared to the control group. The extract also showed the reduction in the number of leukocytes in inflammatory exudate (32.23% compared to the control group) at the dose of 16.8 g/kg (leaf weight/body weight). The results strongly suggested the extract of *V. negundo* leaves had activity against acute inflammatory conditions. The extract was also shown to reduce the granulomas weight (40.20 and 41.24 %) in the chronic granulomas inflammatory mouse model at the doses of 9.6 and 28.8 g/kg (leaf weight/body weight). respectively, which was comparable to methylprednisolone at the dose of 10 mg/ kg. The experiment used a carrageenan-impregnated asbestos implanted under the skin of experimental mice. The immune system of mouse would be activated but it would not be able to eliminate the inflammatory inducer, therefore causing chronic inflammatory conditions. This indicated that the extract also showed activity against chronic inflammation, and the magnitude of activity was comparable to that of methylprednisolone. Previous studies had also indicated that V. negundo extracts displayed potent anti-inflammation effects on the carrageenan-induced edema rat. Chattopadhyay and colleagues (2012) showed that the V. negundo leaf oil decreased the maximum edema to 29% at the dose of 500 µL/kg (Chattopadhyay et al., 2012). In a different case, Kulkarni (2008) reported that the 50% methanol extract of V. negundo leaves at a dose of 100 mg/kg decreased the edema to 69.08%. In a different case, Vinuchakkaravarthy's group (2011) showed that tris(2,4di-tert-butylphenyl) phosphate was isolated from the of V. negundo leaves, which reduced the raw paw edema volume significantly at the tested doses of 50 mg/kg and 70 mg/kg (Vinuchakkaravarthy et al., 2011). These results strongly indicated the effects of V. negundo leaves on the acute inflammatory conditions.

However, in our experiment, there was no doseresponse effect observed and the high dose (16.8 g/kg) was not effective in the carrageenan-induced edema rat model. *V. negundo* constituents, such as lignans (Singh *et al.*, 2005), glycoside steroid, and triterpenoid glycoside (Chen *et al.*, 2014), might stimulate the immune system with the anti-cancer potential. Therefore, it was possible that the high dose (16.8 g/kg) could stimulate these immune systems. In such cases, we did not see the anti-inflammatory effects of the *V. negundo*. Thus, in future studies, we need to conduct more experiments with the other doses as well as study detailed molecular mechanism of action of *V. negundo* leaves.

There were several studies on mechanism of antiinflammatory activities of agnuside. Suksamrarn *et al.* (2002) reported the anti-inflammatory effects of agnuside *in vitro*, which revealed the mechanism of action through selective COX-2 inhibition using COX deficient murine cell lines (Suksamrarn *et al.*, 2002) while Pandey and colleagues (2012) proved that the anti-arthritic activity of agnuside was associated with the suppression of inflammatory mediators (PGE2 and LTB4) and T-cell-mediated cytokines (Th1/Th2). Moreover, agnuside was also found to inhibit vascular permeability and leukocyte migration in rat models (Pandey *et al.*, 2012). Other groups of compounds, such as triterpenoid, lignan, labdane and megastimane derivatives, also exhibited potent inhibitory activities on NO production in lipopolysaccharide (LPS)-induced inflammation in RAW264.7 macrophages and microglial BV-2 cells (Hu *et al.*, 2016; Li *et al.*, 2014; Xu *et al.*, 2019).

In conclusion, the current study provided wide range of scientific evidences to support the traditional usage and clinical application of *V. negundo* leaves in particular case of Vietnam, as well as a validated method for quality control for this plant and its related herbal products in the future.

ACKNOWLEDGMENTS

The authors would like to express our deep gratitude towards the Department of Science and Technology of Hanoi, Vietnam for having funded our research and Department of Pharmacology, Hanoi Medical University, Vietnam for facilities and technical advices in animal experiments.

SUPPLEMENTARY INFORMATION

The NMR data (¹H, ¹³C, COSY, HSQC, HMBC, NOESY), HR-ESIMS, and CD spectra of compound **3**, as well as histopathological findings of granuloma images can be found in Supplementary information.

CONFLICTS OF INTEREST

The authors declare no conflict of interest

REFERENCES

Ankier SI. New hot plate tests to quantify antinociceptive and narcotic antagonist activities. Eur J Pharmacol. 1974;27(1):1-4.

Baghdikian B, Lanhers MC, Fleurentin J, Ollivier E, Maillard C, Balansard G, et al. An analytical study, anti-inflammatory and analgesic effects of *Harpagophytum procumbens* and *Harpagophytum zeyheri*. Planta Med. 1997;63(2):171-176.

Chattopadhyay P, Hazarika S, Dhiman S, Upadhyay A, Pandey A, Karmakar S, et al. *Vitex negundo* inhibits cyclooxygenase-2 inflammatory cytokine-mediated inflammation on carrageenan-induced rat hind paw edema. Pharmacognosy Res. 2012;4(3):134-137.

Chen J, Fan CL, Wang Y, Ye WC. A new triterpenoid glycoside from Vitex negundo. Chin J Nat Med. 2014;12(3): 218-221.

Dharmasiri MG, Jayakody JRAC, Galhena G, Liyanage SSP, Ratnasooriya WD. Anti-inflammatory and analgesic activities of mature fresh leaves of *Vitex negundo*. J Ethnopharmacol. 2003;87(2):199-206.

Gill BS, Mehra R, Navgeet, Kumar S. *Vitex negundo* and its medicinal value. Mol Biol Rep. 2018;45(6):2925-2934.

Gupta RK, Tandon VR. Antinociceptive activity of *Vitex negundo* Linn leaf extract. Indian J Physiol Pharmacol. 2005;49(2):163-170.

Hu P, Li DH, Hu X, Li SG, Sai CM, Sun XC, et al. Lignans and triterpenoids from *Vitex negundo* var. heterophylla and their biological evaluation. Fitoterapia. 2016;111:147-153.

Hu P, Li DH, Jia CC, Liu Q, Wang XF, Li ZL, et al. Bioactive constituents from *Vitex negundo* var. heterophylla and their antioxidant and α -glucosidase inhibitory activities. J Funct Foods. 2017;35:236-244.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, I., ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology Q2(R1). Place, Published. 2005.

Koster R, Anderson M, de Beer E. Acid acetic for analgesic screening. Fed Proc. 1952;18:412.

Kulkarni RR, Virkar DA, Priscilla D'Mello. Antioxidant and antiinfl ammatory activity of Vitex negundo. Indian J Pharm Sci. 2008;70(6):838-840.

Lanhers MC, Fleurentin J, Mortier F, Vinche A, Younos C. Anti-inflammatory and analgesic effects of an aqueous extract of *Harpagophytum procumbens*. Planta Med. 1992;58(2):117-123.

Li MM, Su XQ, Sun J, Gu YF, Huang Z, Zeng KW, et al. Anti-inflammatory ursane- and oleanane-type triterpenoids from *Vitex negundo* var. *cannabifolia*. J Nat Prod. 2014;77(10):2248-2254. National Institute of Medicinal Materials, Medicinal plants and animals in Vietnam. Place, Published Science and Technics Publishing House. 2006.

Okuyama E, Fujimori S, Yamazaki M, Deyama T. Pharmacologically active components of *Viticis fructus* (*Vitex rotundifolia*). II. The component having analgesic effects. Chem Pharm Bull. 1998;46(4):655-662.

Pandey A, Bani S, Satti NK, Gupta BD, Suri KA. Antiarthritic activity of agnuside mediated through the downregulation of inflammatory mediators and cytokines. Inflamm Res 2012;61(4):293-304.

Ryu KH, Rhee HI, Kim JH, Yoo H, Lee BY, Um KA, et al. Anti-inflammatory and analgesic activities of SKLJI, a highly purified and injectable herbal extract of *Lonicera japonica*. Biosci Biotechnol Biochem. 2010;74(10):2022-2028.

Singh DD, Chitra G, Singh IP, Bhutani KK. Immunostimulatory compounds from *Vitex negundo*. Indian J Chem B. 2005;44:1288-1290.

Suksamrarn A, Kumpun S, Kirtikara K, Yingyongnarongkul B, Suksamrarn S. Iridoids with anti-inflammatory activity from *Vitex peduncularis*. Planta Med. 2002;68(1):72-73.

Vinuchakkaravarthy T, Kumaravel KP, Ravichandran S, Velmurugan D. Active compound from the leaves of Vitex negundo L. shows anti-inflammatory activity with evidence of inhibition for secretory Phospholipase A(2) through molecular docking. Bioinformation 2011;7(4):199-206.

Vogel HG. Analgesic, Anti-Inflammatory, and Anti-Pyretic Activity. In: Drug discovery and evaluation: pharmacological assays. 3rd completely rev., updated, and enl. ed. Berlin New York: Springer. 2008:984-1116.

Vu PX. Vietnam flora. Place, Published Science and Technics Publishing House. 2007.

Wang LY, Chen MH, Wu J, Sun H, Liu W, Qu YH, et al. Bioactive glycosides from the twigs of *Litsea cubeba*. J Nat Prod. 2017;80(6):1808-1818.

Wang Y, Zhang R, Xie J, Lu J, Yue Z. Analgesic activity of catalpol in rodent models of neuropathic pain, and its spinal mechanism. J Cell Biochem. 2014;70(3):1565-1571.

Winter CA, Risley EA, Nuss GW. Carrageenin induced edema in hind paw of the rat as an assay for anti-inflamatoly drug. Proc. Soc. Exp. Biol. 1962;111:544-574.

Xiong H, Zheng Y, Yang G, Wang H, Mei Z. Triterpene saponins with anti-inflammatory activity from the stems of *Entada phaseoloides*. Fitoterapia. 2015;103:33-45.

Xu JM, Hu BC, Yuan L, Wu YL, Luan SS, Yuan T, et al. Labdanes and megastigmanes from *Vitex negundo* var. *heterophylla*. Fitoterapia. 2019;137:104265-104265.

Yang LR, Xiong J, Tan NH, Chu HB, Xu L, Li MY. Chemical constituents of *Pedicularis tricolor* (Scrophulariaceae). Acta Botanica Yunnanica. 2006;28(5):553-557.

Zheng CJ, Li HQ, Ren SC, Xu CL, Rahman K, Qin LP, et al. Phytochemical and pharmacological profile of *Vitex negundo*. Phytother Res. 2015;29(5):633-647.

Zheng Y, Yin X, Huo F, Xiong H, Mei Z. Analgesic effects and possible mechanisms of iridoid glycosides from *Lamiophlomis rotata* (Benth.) Kudo in rats with spared nerve injury. J Ethnopharmacol. 2015;173:204-211.

> Received for publication on 02nd July 2019 Accepted for publication on 04th January 2021

SUPPLEMENTARY DATA



Figure S1.1 - ¹H NMR spectrum of compound **3** (400 MHz, methanol- d_{a}).



Figure S1.2 - ¹³C NMR spectrum of compound **3** (100 MHz, methanol- d_{a})

Page 16/24

Necrotic tissues



Figure S1.3 - COSY spectrum of compound 3 (400 MHz, methanol-d4)



Figure S1.4 - HSQC spectrum of compound 3 (400 MHz, methanol-d4)



Figure S1.5 - HMBC spectrum of compound 3 (400 MHz, methanol-d4)



Figure S1.6.1 - NOESY spectrum of compound 3 (aglycon, 400 MHz, methanol-d4)

Phytochemical investigation on Vitex negundo leaves and their anti-inflammatory and analgesic activities



Figure S1.6.2 - NOESY spectrum of compound 3 (sugar, 400 MHz, methanol-d4)



Figure S1.7 - CD spectrum of compound 3 (methanol, 40 $\mu M)$

Mass Spectrum SmartFormula Report

Analysis Info					Acq	uisition D)ate 4/	15/201	9 9:53:11 A	M		
Analysis Name Method Sample Name Comment	nalysis Name D:\Data\Pharmakognosie\Siggi\190415\VNE671a_neg_190 lethod spritze Hieu jan 2019.m ample Name VNE671a_neg_190415 omment					90415.d Ope Inst	erator rument /	Si Ser# m	Simon micrOTOF-Q II 10202			
Acquisition Par	amete	r										
Source Type Focus Scan Begin Scan End	E N 1 1	SI ot active 00 m/z 500 m/z	lon P Set C Set E Set C	Polarity Capillary End Plate Offs Collision Cell	set RF	Negative 3500 V -500 V 352.4 Vpp		Set Ne Set Dry Set Dry Set Div	bulizer / Heater / Gas /ert Valve		4.4 psi 180 °C 4.0 l/min Source	
Intens. x106 1.25 1.00 0.75 0.50 0.25			543.24	18						-M	S, 0.0-1.0mir	n #(2-60)
		357.1135					961.4874	1087.49	935			-
0.00-	όo	400		600		800	100	00	120	0	1400) m/z
Meas. m 543.241	/z # 18 1	Formula C 26 H 39 O 12	Score 100.00	m/z 543.2447	err	[mDa] err 2.9	[ppm] 1 5.4	mSigma 71.6	rdb e 7.5 e	Conf	N-Rule ok	

Figure S1.8 - HR-ESIMS of compound 3



Figure 2.1 - Biological control: A large necrotic tissues and a large number of degenerated polymorphonuclear leukocytes in the center (HE x 400).



Degenerated neutrophils

Fibroblasts





Degenerated neutrophils

Figure 2.3 - The *V.negundo* leaves at the dose of 9.6 g/kg. Necrotic tissues and a large number of degenerated neutrophils in the center (HE x 400).



Fibroblasts

Figure 2.4 - The V.negundo leaves at the dose of 9.6 g/kg: Blood vessels, fibroblasts, some neutrophils and lymphocytes in the septum (HE x 400).



Figure 2.5 - The V.negundo leaves at the dose of 9.6 g/kg: Abscess shell has some lymphocytes and plasmocytes (HE x 400).



Figure 2.6 - The V.negundo leaves at the dose of 28.8 g/kg: Necrotic tissues and degenerated neutrophils at the center of abscess (HE x 400).



Fibroblasts

Figure 2.7 - The V.negundo leaves at the dose of 28.8 g/kg: A large number of fibroblasts, blood vessels and neutrophils, very few lymphocytes (HE x 400).



Figure 2.8 - The V.negundo leaves at the dose of 28.8 g/kg: A few lymphocytes and cytoplasms at the outer of the abscess shell (HE x 400).